Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 155-162

  Gorelick, Philip B ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Alzheimer's disease; Cognitive impairment; Inflammation; Nonsteroidal antiinflammatory drugs; Stroke; Vascular cognitive impairment

Indexed keywords

APOLIPOPROTEIN E4; C REACTIVE PROTEIN; CD40 LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; AUTACOID; BIOLOGICAL MARKER;

COGNITIVE DEFECT; DISEASE ASSOCIATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; MEMORY DISORDER; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AGED; CLINICAL TRIAL; DEMENTIA; EPIDEMIOLOGY; IMMUNOTHERAPY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DEMENTIA; EPIDEMIOLOGIC STUDIES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATION MEDIATORS; METABOLIC SYNDROME X;

EID: 78149245073     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05726.x     Document Type: Review

References (45)

1. Launer, L.J. 2003. Nonsteroidal anti-inflammatory drugs and Alzheimer disease. What's next? JAMA 289: 2865-2867.
2. Craft, S. 2009. The role of metabolic disorders in Alzheimer disease and vascular dementia. Arch. Neurol. 66: 300-305.
3. Gorelick, P.B. & M. William. 2005. Feinberg lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 36: 875-879.
4. Gorelick, P.B. 1999. Can we save the brain from the ravages of midlife cardiovascular risk factors? Neurology 52: 1114-1115.
5. Gorelick, P.B., T. Erkinjuntii, A. Hofman, et al. 1999. Prevention of vascular dementia. Alzheimer Dis. Assoc. Disord. 13(Suppl 3): S131-S139.
6. Iadecola, C. & P.B. Gorelick. 2003. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34: 335-337.
7. Vagnucchi, A.H. & W.W. Li. 2003. Alzheimer's disease and angiogensis. Lancet 361: 605-608.
8. Schneider, J.A., P.A. Boyle, Z. Arvanitakis, et al. 2007. Subcortical infarcts, Alzheimer's disease, pathology, and memory function in older persons. Ann. Neurol. 62: 59-66.
9. Iadecola, C. & P.B. Gorelick. 2004. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 35: 348-350.
10. Aktas,O.,O.Ullrich,C. Infante-Duarte, et al. 2007.Neuronal damage in brain inflammation. Arch. Neurol. 64: 185-189.
11. Noble, J.M., J.J. Manly, N. Schupf, et al. 2010. Association of C-reactive protein with cognitive impairment. Arch. Neurol. 67: 87-92.
12. Sonnen, J.A., E.B. Larson, S.L. Gray, et al. 2009. Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking.Ann.Neurol. 65: 226- 229.
13. Jefferson, A.L., J.M. Massaro, P.A. Wolf, et al. 2007. Inflammatory biomarkers are associated wit total brain volume. The Framingham Heart Study. Neurology 68: 1032-1038.
14. Schmidt, R., H. Schmidt, J.D. Curb, et al. 2002. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. 52: 168-174.
15. Weaver, J.D., M.-H. Huang, M. Albert, et al. 2002. Interleukin-6 and risk of cognitive decline. MacArthur Studies of Successful Aging. Neurology 59: 371-378.
16. Yaffe, K., A. Kanaya, K. Lindquist, et al. 2004. Themetabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292: 2237-2242.
17. Holmes, C., C. Cunningham, E. Zotova, et al. 2009. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73: 768-774.
18. Furie, K.L. & E.E. Smith. 2007. Metabolic syndrome. A target for preventing leukoaraiosis and age-related dementia? Neurology 69: 951-952.
19. Vanhanen, M., K. Koivisto, L. Moilanan, et al. 2006. Association of metabolic syndrome with Alzheimer disease. A population-based study. Neurology 67: 843-847.
20. Yaffe, K., A.L. Weston, T. Blackwell & K.A. Krueger. 2009. The metabolic syndrome and development of cognitive impairment among older women. Arch. Neurol. 66: 324-328.
21. Razay, G.,A.Vreugdenhil&G.Wilcock. 2007. Themetabolic syndrome and Alzheimer disease. Arch. Neurol. 64: 93-96.
22. Van Den Berg, E.,G.J. Biessels, A.J.M. de Craen, et al. 2007. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 69: 979-985.
23. Beard, C.M., S.C. Waring, P.C. O'Brien, et al. 1998. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin. Proc. 73: 951-955.
24. INT'Veld, B.A., A. Ruitenberg, A.Hofman, et al. 2001.Nonsteroidal antiinflammatory drugs and the risk of Alzheimers disease. N. Engle. J. Med. 345: 1515-1521.
25. Anthony, J.C., J.C.S. Breitner, P.P. Zandi, et al.; on behalf of the Cache County Memory Study Group. 2000. Reduced prevalence ofADin users ofNSAIDs andH2 receptor antagonists: the Cache County Study. Neurology 54: 2066-2071.
26. Zandi, P.P., J.C. Anthony, K.M. Hayden, et al. 2002; for the Cache County Study Investigators. Reduced incidence ofAD with NSAID but not H2 receptor antagonists. Neurology 59: 880-886.
27. Broe, G.A., D.A. Grayson, H.M. Creasey, et al. 2000. Antiinflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57: 1586-1591.
28. Wolfson, C., A. Perrault, Y. Moride, et al. 2002. A casecontrol analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective? Neuroepidemiology 21: 81-86.
29. Vlad, S.C., D.R. Miller, N.W. Kowall & D.T. Felson. 2008. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70: 1672-1677.
30. Hayden, K.M., P.P. Zandi, A.S. Khachaturian, et al.; for the Cache County Investigators. 2007. Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology 69: 275-282.
31. Szekely, C.A., J.C.S. Breitner, A.L. Fitzpatrick, et al. 2008. NSAID use and dementia risk in the Cardiovascular Health Study. Role of APOE and NSAID type. Neurology 70: 17-24.
32. Grodstein, F., K.A. Skarupski, J.L. Bienias, et al. 2008. Antiinflammatory agents and cognitive decline in a bi-racial population. Neuroepidemiology 30: 45-50.
33. Arvanitakis,Z., F.Grodstein, J.L.Bienias, et al. 2008.Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70: 2219-2225.
34. Breitner, J.C.S., S.J.P.A. Haneuse, R.Walker, et al. 2009. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72: 1899-1905.
35. Aisen, P.S., K.A. Schafer, M. Grundman, et al.; for the Alzheimer's Cooperative Study. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. JAMA 289: 2819-2826.
36. ADAPT Research Group. 2007. Naproxen and celecoxib do not preventADin early results froma randomized controlled trial. Neurology 68: 1800-1808.
37. ADAPT ResearchGroup. 2008.Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65: 896-905.
38. Gilman, S., M. Koller, R.S. Black, et al. for the AN1792 (QS-21)-201 Team. 2005. Clinical effects of AB immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
39. Relkin, N.R. 2008. Current state of immunotherapy for Alzheimer's disease. CNS Spectr. 13(Suppl 16): 39-41.
40. Tsakanikas, D. & N. Relkin. 2010. Neuropsychological outcomes following 18-months of uninterrupted intravenous immunoglobulin (IVIG) treatment in patients with Alzheimer's disease. Neurology 74(Suppl 2):A395-A396 (abstract).
41. Kang, J.H., N. Cook, J.Manson, et al. 2007. Low dose aspirin and cognitive function in thewomen's health study cognitive cohort. BMJ 334: 987.
42. Price, J.F., M.C. Stewart, I.J. Deary, et al. 2008. Low dose aspirin and cognitive function in middle aged to elderly adults: randomized controlled trial. BMJ 337: a1198.
43. Bentham, P., R. Gray, E. Sellwood, et al. 2008. Aspirin in Alzheimer's disease (AD2000): a randomized open-label trial. Lancet Neurol. 7: 41-49.
44. Diener, H.C., R.L. Sacco, S. Yusuf, et al. 2008. Effects of aspirin plus extended-release dipyridamole versus telmisartan on disability and cognitive function after recurrent stroke in patients with ischemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7: 875-884.
45. Nelson, M., C. Reid, L.J. Beilin, et al.; Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. 2003. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly. Drugs Aging 20: 897-903.